KRAS and cancer: Accompanying this, we further observed that only 70 kDa dextran achieved a persistent, nonsaturable, enhanced cellular entry into KRAS mutant cancer cells over KRAS wild-type cells, as identified through a flow cytometer-aided long-term kinetic investigation (Figure 1D and 1E), which was in clear contrast to the irregular pattern for the 4 kDa (Figure 1F) and 150 kDa (Figure 1G) dextrans.